Publikationen, an denen er mitarbeitet Paula Aranaz Oroz (19)

2021

  1. In vivo testing of mucus-permeating nanoparticles for oral insulin delivery using Caenorhabditis elegans as a model under hyperglycemic conditions

    Acta Pharmaceutica Sinica B, Vol. 11, Núm. 4, pp. 989-1002

2020

  1. A combination of borage seed oil and quercetin reduces fat accumulation and improves insulin sensitivity in obese rats

    Food and Function, Vol. 11, Núm. 5, pp. 4512-4524

  2. Phenolic compounds reduce the fat content in caenorhabditis elegans by affecting lipogenesis, lipolysis, and different stress responses

    Pharmaceuticals, Vol. 13, Núm. 11, pp. 1-33

2019

  1. Broccoli extract improves high fat diet-induced obesity, hepatic steatosis and glucose intolerance in Wistar rats

    Journal of Functional Foods, Vol. 59, pp. 319-328

  2. Low doses of cocoa extract supplementation ameliorate diet-induced obesity and insulin resistance in rats

    Food and Function, Vol. 10, Núm. 8, pp. 4811-4822

  3. Phenolic compounds inhibit 3T3-L1 adipogenesis depending on the stage of differentiation and their binding affinity to PPARγ

    Molecules, Vol. 24, Núm. 6

2018

  1. Borago officinalis seed oil (BSO), a natural source of omega-6 fatty acids, attenuates fat accumulation by activating peroxisomal beta-oxidation both in C. elegans and in diet-induced obese rats

    Food and Function, Vol. 9, Núm. 8, pp. 4340-4351

  2. Cyclodextrin-grafted poly(anhydride) nanoparticles for oral glibenclamide administration. In vivo evaluation using C. elegans

    International Journal of Pharmaceutics, Vol. 547, Núm. 1-2, pp. 97-105

  3. Dihomo-gamma-linolenic acid induces fat loss in: C. Elegans in an omega-3-independent manner by promoting peroxisomal fatty acid β-oxidation

    Food and Function, Vol. 9, Núm. 3, pp. 1621-1637

2017

  1. p.Y317H is a new JAK2 gain-of-function mutation affecting the FERM domain in a myelofibrosis patient with CALR mutation

    Haematologica

2014

  1. A simple approach for classifying new mutations as somatic or germinal in DNA samples lacking paired tissue

    BioTechniques, Vol. 56, Núm. 6, pp. 327-329

  2. Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling

    Leukemia

2013

  1. CBL RING finger deletions are common in core-binding factor acute myeloid leukemias

    Leukemia and Lymphoma

2012

  1. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia

    Leukemia and Lymphoma

  2. CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2

    Haematologica, Vol. 97, Núm. 8, pp. 1234-1241

2011

  1. LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation

    Leukemia Research, Vol. 35, Núm. 11, pp. 1537-1539

2010

  1. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes

    Cancer Genetics and Cytogenetics, Vol. 199, Núm. 1, pp. 1-8

  2. Quantification of PDGFRA alternative transcripts improves the screening for XPDGFRA fusions by reverse transcriptase-polymerase chain reaction

    Leukemia and Lymphoma, Vol. 51, Núm. 9, pp. 1720-1726

2008

  1. Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs

    Leukemia Research